

OVERVIEW

- Focused on the development of Bucillamine for infectious diseases, inflammatory disorders and medical countermeasures
- Advancing use of Bucillamine for nerve agent exposure with the Defence Research and Development Canada (DRDC)
- Robust patent portfolio covering methods and compositions
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

Focus on Infectious Diseases and Medical Countermeasures


Product	Indication	Stage of Development	Regulatory Status
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases COVID-19	Completed Phase 3	Determining next steps and international opps
Bucillamine	Medical Countermeasures Nerve Agent	Pre-clinical	Defence R&D Canada – Research funded by Sullfield Research Centre, Canadian Department of National Defence

STRATEGIC PARTNERS



EXPECTED MILESTONES & STRATEGY

- ▶ Q1-26: Results of Bucillamine for nerve agent exposure at DRDC
- ▶ Q2-26: Further initiatives for Bucillamine DRDC



TEAM

Management

Michael Frank, Chairman & CEO
Carmelo Marrelli, CFO

Scientific and Clinical

Dr. Kelly McKee, Dr. Arshi Kizilbash, M.D., Dr. Osnesmo Mpanju, Regulatory Affairs

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

CONTACT INFORMATION

Revive Therapeutics Ltd.
82 Richmond Street East
Toronto, ON M5C 1P1

Tel: 1-888-901-0036
E-mail: info@revivether.com
Website: revivether.com

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF, FRANKFURT: 31R
Share Price:	\$0.01 (Feb 13, 2026)
52-week High / Low:	CAD \$0.035 / \$0.005
Shares Outstanding:	418,564,269 common shares 35,320,334 stock options 63,317,263 warrants (\$0.05 - \$0.20)
Market Cap:	CAD ~ 4,000,000